Evidence map›Paper›PMID 35273385›Full record

ReviewNature reviews. Rheumatology2022

Treatment of axial spondyloarthritis: an update.

Abhijeet Danve, Atul Deodhar

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07130331 (Efficacy and Influencing Factors Analysis of Secukinumab in Patients With Axial Spondyloarthritis in a Real-World Setting), which is not on this map. Cited by 97 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 3 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07130331 completednot on this map

Efficacy and Influencing Factors Analysis of Secukinumab in Patients With Axial Spondyloarthritis in a Real-World Setting

TypeobservationalSponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolRan2020 to 2025Enrolled200ConditionsAxial Spondylarthritis (axSpA), SecukinumabArmsSecikinumab
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Fibroblast activation protein-targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Abhijeet DanveSection of Rheumatology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
Atul DeodharDivision of Arthritis & Rheumatic diseases, Oregon Health & Science University, Portland, OR, USA. deodhara@ohsu.edu.ORCID http://orcid.org/0000-0002-2130-1246
Oregon Health & Science University · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life. The four broad categories of approved treatment options are physical therapy and exercise (which have been known to be beneficial for millennia), NSAIDs (since the 1950s), TNF inhibitors (first FDA approval in 2003) and IL-17 inhibitors (first FDA approval in 2016). In addition, there have been a host of new developments in the axSpA field, including new treatment guidelines, the FDA approval of three biologic DMARDs to treat non-radiographic axSpA, the FDA and EMA approval of Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biologic DMARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or stopping TNF inhibitors in patients in remission, trials of treat-to-target strategy in axSpA, and several new molecules in phase III studies. This Review explores the developments in the management of axSpA.

Indexed as

Antirheumatic AgentsAxial SpondyloarthritisBiological ProductsJanus Kinase InhibitorsSpondylarthritisSpondylitis, AnkylosingHumansQuality of LifeTumor Necrosis Factor InhibitorsAntirheumatic AgentsBiological ProductsJanus Kinase InhibitorsTumor Necrosis Factor Inhibitors

Identifiers

PMID35273385
OpenAlexW4221042845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.